[go: up one dir, main page]

GB9908838D0 - Fibroblast inhibitor - Google Patents

Fibroblast inhibitor

Info

Publication number
GB9908838D0
GB9908838D0 GBGB9908838.7A GB9908838A GB9908838D0 GB 9908838 D0 GB9908838 D0 GB 9908838D0 GB 9908838 A GB9908838 A GB 9908838A GB 9908838 D0 GB9908838 D0 GB 9908838D0
Authority
GB
United Kingdom
Prior art keywords
inhibitor
fibroblast
fibroblast inhibitor
fibroblasts
production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB9908838.7A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University College London
Original Assignee
University College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9819921.9A external-priority patent/GB9819921D0/en
Application filed by University College London filed Critical University College London
Priority to GBGB9908838.7A priority Critical patent/GB9908838D0/en
Publication of GB9908838D0 publication Critical patent/GB9908838D0/en
Priority to PCT/GB1999/003092 priority patent/WO2000015250A2/en
Priority to AU58778/99A priority patent/AU5877899A/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

There is disclosed the use of an inhibitor of factor Xa activity in the production of a medicament for the treatment of a condition which is characterised by the proliferation of fibroblasts and/or the production of procollagen by fibroblasts.
GBGB9908838.7A 1998-09-11 1999-04-16 Fibroblast inhibitor Ceased GB9908838D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GBGB9908838.7A GB9908838D0 (en) 1998-09-11 1999-04-16 Fibroblast inhibitor
PCT/GB1999/003092 WO2000015250A2 (en) 1998-09-11 1999-09-13 Fibroblast inhibitor
AU58778/99A AU5877899A (en) 1998-09-11 1999-09-13 Fibroblast inhibitor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9819921.9A GB9819921D0 (en) 1998-09-11 1998-09-11 Inhibition of fibroblast proliferation
GBGB9908838.7A GB9908838D0 (en) 1998-09-11 1999-04-16 Fibroblast inhibitor

Publications (1)

Publication Number Publication Date
GB9908838D0 true GB9908838D0 (en) 1999-06-16

Family

ID=26314362

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9908838.7A Ceased GB9908838D0 (en) 1998-09-11 1999-04-16 Fibroblast inhibitor

Country Status (3)

Country Link
AU (1) AU5877899A (en)
GB (1) GB9908838D0 (en)
WO (1) WO2000015250A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2950813B1 (en) 2013-01-31 2019-09-04 Pfizer Inc Compositions and methods for counteracting factor xa inhibition
US20160235824A1 (en) * 2013-11-01 2016-08-18 The Children's Hospital Philadelphia Compositions and Methods for Increasing the Half-Life of Factor XA
WO2016028872A2 (en) 2014-08-19 2016-02-25 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor ix function

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5385885A (en) * 1988-01-15 1995-01-31 Gasic; Gregory P. Inhibition of smooth muscle cell proliferation by antistasin and tick anticoagulant peptide

Also Published As

Publication number Publication date
WO2000015250A3 (en) 2000-07-20
AU5877899A (en) 2000-04-03
WO2000015250A2 (en) 2000-03-23

Similar Documents

Publication Publication Date Title
NZ297320A (en) 2-(2-amino-3-methoxyphenyl)-4-oxo-4h-[1]-benzopyran and medicaments
MX9709915A (en) Peptidyl heterocycles useful in the treatment of thrombin related disorders.
DE69631423D1 (en) CHINOLONES AND THEIR THERAPEUTIC USE
MY117798A (en) Use of a rapamycin derivative in vasculopathies and xenotransplantation
AU7321598A (en) Use of cholinesterase inhibitors to treat disorders of attention
EP2783686A8 (en) Combination of a rapamycin derivative and letrozole for treating breast cancer
MX9800922A (en) Quinolones and their therapeutic use.
PL352399A1 (en) Substituted benzimidazoles
GB2365772A (en) Factor
EP1041982A4 (en) INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS
CA2301032A1 (en) A method of preventing or treating estrogen-dependent diseases and disorders
UA66793C2 (en) Leptin as inhibitor of tumor growth
AU4069095A (en) Medicaments for the treatment of restenosis and arterial sclerosis
EP1039916B8 (en) Use of at least one fucane for the manufacture of a medicament for the treatment of periodontal pathologies
ZA964753B (en) Inhibitors of Factor Xa.
MX9805290A (en) Use of inhibitors of the activity of retinoic acid for treating sensitive skin.
ES2091712A1 (en) Synergising association having an antagonist effect on nk1 and nk2 receptors.
GB9908838D0 (en) Fibroblast inhibitor
ATE487697T1 (en) IMINOCYCLITOL INHIBITORS OF HEXOAMINIDASE AND GLYCOSIDASE
HK1047695A1 (en) Use of beta-adrenoceptor antagonists for the manufacture of a medicament for the treatment of disorders of the outer retina
IL131478A0 (en) Methods for treatment of scar tissue
IL130500A (en) Use of comt inhibitors for the manufacture of a medicament for the prevention of diabetic vascular dysfunctions
AU2444399A (en) New use for pain management
NZ299623A (en) Neutrophil Inhibitory Factor, treatment of autoimmune disease
ZA9610073B (en) Method of using beta-interferons to treat restenosis

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)